Bolhuis Thomas E, Marsman Diane, van den Hoogen Frank H J, Broeder Alfons A den, Broeder Nathan den, van der Maas Aatke
Department of Rheumatology, Sint Maartenskliniek, Ubbergen, The Netherlands.
Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
BMC Rheumatol. 2022 Aug 2;6(1):45. doi: 10.1186/s41927-022-00274-y.
To develop and assess a prediction model for polymyalgia rheumatica (PMR) relapse within the first year of glucocorticoid (GC) treatment.
A retrospective PMR cohort (clinical diagnosis) from a rheumatology department was used. All visits > 30 days after starting GC treatment and with > 2.5 mg/day oral prednisolone were used as potential relapse visits. Often used relapse criteria (1) rheumatologist judgement, (2) treatment intensification-based relapse) were assessed for agreement in this cohort. The proportion of patients with treatment-based relapse within 1 and 2 years of treatment and the relapse incidence rate were used to assess unadjusted associations with candidate predictors using logistic and Poisson regression respectively. After using a multiple imputation method, a multivariable model was developed and assessed to predict the occurrence (yes/no) of relapse within the first year of treatment.
Data from 417 patients was used. Relapse occurred at 399 and 321 (of 2422) visits based on the rheumatologist judgement- and treatment-based criteria respectively, with low to moderate agreement between the two (87% (95% CI 0.86-0.88), with κ = 0.49 (95% CI 0.44-0.54)). Treatment-based relapse within the first two years was significantly associated with CRP, ESR, and pre-treatment symptom duration, and incidence rate with only CRP and ESR. A model to predict treatment intensification within the first year of treatment was developed using sex, medical history of cardiovascular disease and malignancies, pre-treatment symptom duration, ESR, and Hb, with an AUC of 0.60-0.65.
PMR relapse occurs frequently, although commonly used criteria only show moderate agreement, underlining the importance of a uniform definition and criteria of a PMR specific relapse. A model to predict treatment intensification was developed using practical predictors, although its performance was modest.
开发并评估一种用于预测糖皮质激素(GC)治疗的第一年中风湿性多肌痛(PMR)复发的模型。
使用来自风湿病科的回顾性PMR队列(临床诊断)。开始GC治疗30天以上且口服泼尼松龙剂量>2.5mg/天的所有就诊被用作潜在的复发就诊。在该队列中评估常用的复发标准(1)风湿病学家的判断,(2)基于治疗强化的复发)的一致性。分别使用逻辑回归和泊松回归,以治疗1年和2年内基于治疗的复发患者比例和复发发生率来评估与候选预测因素的未调整关联。在使用多重填补方法后,开发并评估一个多变量模型以预测治疗第一年复发的发生(是/否)。
使用了417例患者的数据。根据风湿病学家的判断标准和基于治疗的标准,分别在399次和321次(共2422次)就诊时出现复发,两者之间的一致性为低到中度(87%(95%CI 0.86 - 0.88),κ = 0.49(95%CI 0.44 - 0.54))。前两年基于治疗的复发与CRP、ESR和治疗前症状持续时间显著相关,而发病率仅与CRP和ESR相关。使用性别、心血管疾病和恶性肿瘤病史、治疗前症状持续时间、ESR和Hb建立了一个预测治疗第一年治疗强化的模型,AUC为0.60 - 0.65。
PMR复发频繁发生,尽管常用标准仅显示中度一致性,这突出了PMR特异性复发的统一定义和标准的重要性。使用实际的预测因素开发了一个预测治疗强化的模型,但其性能一般。